Adeline Berger

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil

19 publications

Tumor dormancy: EMT beyond invasion and metastasis.
Aouad P., Quinn H.M., Berger A., Brisken C. Genesis. Peer-reviewed.
Translational screening platform to evaluate chemotherapy in combination with focal therapy for retinoblastoma.
Sinenko I.L., Kuttler F., Simeonov V., Moulin A., Aouad P., Stathopoulos C., Munier F.L., Berger A., Dyson P.J., 2023/09. Cancer science, 114 (9) pp. 3728-3739. Peer-reviewed.
Abstract 3541: Tumoroid-based screening platform to test focal, chemo- and combination therapy for retinoblastoma
Sinenko Irina, Kuttler Fabien, Simeonov Valentin, Moulin Alexandre, Stathopoulos Christina, Turcatti Gerardo, Berger Adeline, Munier Francis, Dyson Paul, 2023/04/04. pp. 3541-3541 dans Cancer Research. Peer-reviewed, American Association for Cancer Research (AACR).
Retinoblastoma: From genes to patient care.
Bouchoucha Y., Matet A., Berger A., Carcaboso A.M., Gerrish A., Moll A., Jenkinson H., Ketteler P., Dorsman J.C., Chantada G. et al., 2023/01. European journal of medical genetics, 66 (1) p. 104674. Peer-reviewed.
Lentiviral Vectors for Ocular Gene Therapy.
Arsenijevic Y., Berger A., Udry F., Kostic C., 2022/07/31. Pharmaceutics, 14 (8) p. 1605. Peer-reviewed.
AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
Kim Seaho, Au CheukMan C, Jamalruddin Mohd Azrin Bin, Abou-Ghali Naira Essam, Mukhtar Eiman, Portella Luigi, Berger Adeline, Worroll Daniel, Vatsa Prerna, Rickman David S et al., 2022/07/18. eLife, 11. Peer-reviewed.
Enhancer of Zeste Homolog 2 (EZH2) Contributes to Rod Photoreceptor Death Process in Several Forms of Retinal Degeneration and Its Activity Can Serve as a Biomarker for Therapy Efficacy.
Mbefo M., Berger A., Schouwey K., Gérard X., Kostic C., Beryozkin A., Sharon D., Dolfuss H., Munier F., Tran H.V. et al., 2021/08/28. International journal of molecular sciences, 22 (17) p. 9331. Peer-reviewed.
Pharmacological disruption of the Notch transcription factor complex.
Lehal R., Zaric J., Vigolo M., Urech C., Frismantas V., Zangger N., Cao L., Berger A., Chicote I., Loubéry S. et al., 2020/07/14. Proceedings of the National Academy of Sciences of the United States of America, 117 (28) pp. 16292-16301. Peer-reviewed.
An in vitro Model of Human Retinal Detachment Reveals Successive Death Pathway Activations.
Potic J., Mbefo M., Berger A., Nicolas M., Wanner D., Kostic C., Matet A., Behar-Cohen F., Moulin A., Arsenijevic Y., 2020. Frontiers in neuroscience, 14 p. 571293. Peer-reviewed.
N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A., Brady N.J., Bareja R., Robinson B., Conteduca V., Augello M.A., Puca L., Ahmed A., Dardenne E., Lu X. et al., 2019/07/01. The Journal of clinical investigation, 129 (9) pp. 3924-3940. Peer-reviewed.
Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.
Lee R.S., Zhang L., Berger A., Lawrence M.G., Song J., Niranjan B., Davies R.G., Lister N.L., Sandhu S.K., Rubin M.A. et al., 2019/04. Neoplasia, 21 (4) pp. 389-400. Peer-reviewed.
The Role of Androgen Receptor in Prostate Cancer
Berger Adeline, Rickman David S., 2018. pp. 345-365 dans Molecular Pathology Library, Springer International Publishing.
Identification of novel prostate cancer drivers using RegNetDriver: a framework for integration of genetic and epigenetic alterations with tissue-specific regulatory network.
Dhingra P., Martinez-Fundichely A., Berger A., Huang F.W., Forbes A.N., Liu E.M., Liu D., Sboner A., Tamayo P., Rickman D.S. et al., 2017/07/27. Genome biology, 18 (1) p. 141. Peer-reviewed.
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E., Beltran H., Benelli M., Gayvert K., Berger A., Puca L., Cyrta J., Sboner A., Noorzad Z., MacDonald T. et al., 2016/10/10. Cancer cell, 30 (4) pp. 563-577. Peer-reviewed.
mRNA trans-splicing in gene therapy for genetic diseases.
Berger A., Maire S., Gaillard M.C., Sahel J.A., Hantraye P., Bemelmans A.P., 2016/07. Wiley interdisciplinary reviews. RNA, 7 (4) pp. 487-498. Peer-reviewed.
Deciphering the molecular basis of invasiveness in Sdhb-deficient cells.
Loriot C., Domingues M., Berger A., Menara M., Ruel M., Morin A., Castro-Vega L.J., Letouzé É., Martinelli C., Bemelmans A.P. et al., 2015/10/20. Oncotarget, 6 (32) pp. 32955-32965. Peer-reviewed.
Repair of rhodopsin mRNA by spliceosome-mediated RNA trans-splicing: a new approach for autosomal dominant retinitis pigmentosa.
Berger A., Lorain S., Joséphine C., Desrosiers M., Peccate C., Voit T., Garcia L., Sahel J.A., Bemelmans A.P., 2015/05. Molecular therapy, 23 (5) pp. 918-930. Peer-reviewed.
Spectral-domain optical coherence tomography of the rodent eye: highlighting layers of the outer retina using signal averaging and comparison with histology.
Berger A., Cavallero S., Dominguez E., Barbe P., Simonutti M., Sahel J.A., Sennlaub F., Raoul W., Paques M., Bemelmans A.P., 2014. PloS one, 9 (5) pp. e96494. Peer-reviewed.
Assessment of human Nter and Cter BRCA1 mutations using growth and localization assays in yeast.
Millot G.A., Berger A., Lejour V., Boulé J.B., Bobo C., Cullin C., Lopes J., Stoppa-Lyonnet D., Nicolas A., 2011/12. Human mutation, 32 (12) pp. 1470-1480. Peer-reviewed.
Unicentre - CH-1015 Lausanne
Tél. +41 21 692 11 11
Swiss University